Revolutionary GI diagnostics and therapeutics are on the horizon

Our ingestible technologies show promising results that could transform clinical diagnostics and therapeutics for GI disease. Read more about the difficulties in diagnosing GI disease and how our technology is an expected solution.

Current Landscape

Current methods for sampling the gut make it difficult for healthcare providers to accurately diagnose and monitor gastrointestinal diseases. Even after diagnosis, drug therapy presents a number of challenges, including achieving the most effective therapeutic dose at the site of disease.

Two meta-analyses presented by Progenity at the 2019 American College of Gastroenterology (ACG) meeting show significant limitations to current diagnostics for small intestine bacterial overgrowth (SIBO) and support the need for novel tools.

Characterization of the bacterial makeup and quantitative distribution in patients with suspected SIBO

A meta-analysis1

Download the poster.

Accuracy of glucose breath testing for SIBO using endoscopy aspirate cultures as a reference standard

A meta-analysis2

Download the poster.

Promising New Tech

Progenity is working to develop diagnostic and therapeutic technology platforms, spearheaded by ingestible devices and supported by a broad and growing intellectual property portfolio, that will address these challenges, including tests for SIBO, nonalcoholic steatohepatitis (NASH), colon cancer, and inflammatory bowel disease (IBD). This latest research represents early steps toward our novel diagnostic and drug therapy approach that should prove transformative for GI medicine.

“Direct administration of drug therapies via ingestible technologies shows tremendous promise to improve treatment outcomes in patients with gastrointestinal diseases. Administering a high therapeutic dose directly to the site of disease with a noninvasive method of delivery could be key to increasing treatment efficacy for these burdensome disorders.”
- William Sandborn, MD, chief of gastroenterology and director of the Inflammatory Bowel Disease Center at UC San Diego Health

Data presented at the 2019 ACG meeting highlight the promise of ingestible technologies for GI disease diagnostics and therapeutics.

Targeted topical anti-α4β7 integrin antibody results in reduced accumulation of α4β7 memory T-cells in gut tissue in DSS-induced colitis mice

This study3 suggests topically delivered anti-α4β7 integrin antibody may be an efficacious treatment in irritable bowel disease.

Download the poster.

Interested in learning more?

Progenity is translating innovation into precision medicine.

Learn more.

  1. Lee NS, et al. Characterization of the bacterial makeup and quantitative distribution in patients with suspected SIBO: A meta-analysis. Poster presented at ACG, 2019. San Antonio, Texas.
  2. Stylli J, et al. Accuracy of glucose breath testing for SIBO using endoscopy aspirate cultures as a reference standard: A meta-analysis. Poster presented at ACG, 2019. San Antonio, Texas.
  3. Lee NS, et al. Targeted topical anti-α4β7 integrin antibody results in reduced accumulation of α4β7 memory T-cells in gut tissue in DSS-induced colitis mice. Poster presented at ACG, 2019. San Antonio, Texas.

Support